[HTML][HTML] Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-…
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-…
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
…, S Zhang, J Wang, S Zhou, S Ren, S Lu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
[HTML][HTML] Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
…, C Grohé, J Wang, JW Goldman, S Lu… - … England Journal of …, 2023 - Mass Medical Soc
Background Among patients with resected, epidermal growth factor receptor (EGFR)–mutated,
stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or …
stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or …
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a …
Background First-line pembrolizumab monotherapy improves overall and progression-free
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR …
survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR …
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international …
…, C Martin, M Pérol, A Scherpereel, S Lu… - The Lancet …, 2021 - thelancet.com
Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …
[HTML][HTML] Multiorgan and renal tropism of SARS-CoV-2
Multiorgan and Renal Tropism of SARS-CoV-2 In this autopsy series, the authors found that
SARS-CoV-2 has an organotropism beyond the respiratory tract, including the kidneys, heart…
SARS-CoV-2 has an organotropism beyond the respiratory tract, including the kidneys, heart…
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from …
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, …
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, …
[HTML][HTML] Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
…, SW Kim, T Kato, HV Vu, S Lu… - … England Journal of …, 2020 - Mass Medical Soc
Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). …
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). …
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised …
…, T Mok, V Hirsh, JCH Yang, KH Lee, S Lu… - The Lancet …, 2016 - thelancet.com
Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine
kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-…
kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-…